Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants

Inclusion criteria: * healthy male or female, between, and including, 56 and 83 days of age. * Born after a gestation period between 36 and 42 weeks * Birth dose of hepatitis B vaccine within the first 72 hours of life Exclusion criteria: * planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of study vaccine, or planned administration during the study period. * Bacille Calmette-Guérin (BCG) vaccine received after the first 2 weeks of life. * History of OR previous vaccination against OR known exposure since birth to diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and/or meningococcal disease. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection * A family history of congenital or hereditary immunodeficiency * History of any neurologic disorders or seizures * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine